AU2011302344B2 - HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients - Google Patents

HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients Download PDF

Info

Publication number
AU2011302344B2
AU2011302344B2 AU2011302344A AU2011302344A AU2011302344B2 AU 2011302344 B2 AU2011302344 B2 AU 2011302344B2 AU 2011302344 A AU2011302344 A AU 2011302344A AU 2011302344 A AU2011302344 A AU 2011302344A AU 2011302344 B2 AU2011302344 B2 AU 2011302344B2
Authority
AU
Australia
Prior art keywords
optionally substituted
indol
triazole
phenyl
mercapto
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011302344A
Other languages
English (en)
Other versions
AU2011302344A1 (en
Inventor
Florentina Teofilovici
Vojo Vukovic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Synta Phamaceuticals Corp
Original Assignee
Synta Phamaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2011/037285 external-priority patent/WO2011146803A1/en
Application filed by Synta Phamaceuticals Corp filed Critical Synta Phamaceuticals Corp
Publication of AU2011302344A1 publication Critical patent/AU2011302344A1/en
Application granted granted Critical
Publication of AU2011302344B2 publication Critical patent/AU2011302344B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011302344A 2010-09-13 2011-09-13 HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients Ceased AU2011302344B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US38240010P 2010-09-13 2010-09-13
US61/382,400 2010-09-13
AUPCT/US2011/037285 2011-05-20
PCT/US2011/037285 WO2011146803A1 (en) 2010-05-20 2011-05-20 Method of treating lung adenocarcinoma with hsp90 inhibitory compounds
PCT/US2011/051320 WO2012037072A1 (en) 2010-09-13 2011-09-13 Hsp90 inhibitors for treating non-small cell lung cancers in wild-type egfr and/or kras patients

Publications (2)

Publication Number Publication Date
AU2011302344A1 AU2011302344A1 (en) 2013-03-28
AU2011302344B2 true AU2011302344B2 (en) 2015-01-15

Family

ID=44674905

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2011302344A Ceased AU2011302344B2 (en) 2010-09-13 2011-09-13 HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients

Country Status (7)

Country Link
US (1) US20120064175A1 (enExample)
EP (1) EP2616063A1 (enExample)
JP (1) JP2013537229A (enExample)
CN (1) CN103269701A (enExample)
AU (1) AU2011302344B2 (enExample)
CA (1) CA2810254A1 (enExample)
WO (1) WO2012037072A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006279794B2 (en) 2005-08-12 2011-04-07 Synta Pharmaceuticals Corp. Pyrazole compounds that modulate HSP90 activity
US20070250391A1 (en) * 2006-04-05 2007-10-25 Prade Hendrik D Merchandising system and method for food and non-food items for a meal kit
WO2007139951A2 (en) 2006-05-25 2007-12-06 Synta Pharmaceuticals Corp. Method for treating proliferative disorders associated with protooncogene products
CA2653329C (en) 2006-05-25 2018-01-16 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
EP2026797A2 (en) 2006-05-25 2009-02-25 Synta Pharmaceuticals Corporation Method for treating non-hodgkin's lymphoma
US9156836B2 (en) * 2008-05-16 2015-10-13 Synta Pharmaceuticals Corp. Tricyclic triazole compounds that modulate HSP90 activity
WO2009148599A1 (en) 2008-06-04 2009-12-10 Synta Pharmaceuticals Corp. Pyrrole compunds that modulate hsp90 activity
WO2009158026A1 (en) 2008-06-27 2009-12-30 Synta Pharmaceuticals Corp. Hydrazonamide compounds that modulate hsp90 activity
PT2328893E (pt) * 2008-08-08 2013-06-27 Synta Pharmaceuticals Corp Compostos de triazol que modulam a actividade da hsp90
TW201011003A (en) 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
KR20120117905A (ko) 2010-01-28 2012-10-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 프로테아좀 활성을 향상시키는 조성물 및 방법
US9205086B2 (en) 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor
PT2707101T (pt) 2011-05-12 2019-05-30 Proteostasis Therapeutics Inc Reguladores da proteostase
WO2013006864A2 (en) 2011-07-07 2013-01-10 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
CA2853799A1 (en) 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors
WO2013067165A1 (en) * 2011-11-02 2013-05-10 Synta Pharmaceuticals Corp. Combination therapy of hsp90 inhibitors with platinum-containing agents
US9402831B2 (en) 2011-11-14 2016-08-02 Synta Pharmaceutical Corp. Combination therapy of HSP90 inhibitors with BRAF inhibitors
EP2849751A1 (en) * 2012-05-10 2015-03-25 Synta Pharmaceuticals Corp. Treating cancer with hsp90 inhibitory compounds
WO2013170182A1 (en) * 2012-05-11 2013-11-14 Synta Pharmaceuticals Corp. Treating cancer with an hsp90 inhibitory compound
WO2013173436A1 (en) * 2012-05-16 2013-11-21 Synta Pharmaceuticals Corp. Pre-selection of subjects for therapeutic treatment with an hsp90 inhibitor based on hypoxic status
WO2014116228A1 (en) 2013-01-25 2014-07-31 President And Fellows Of Harvard College Usp14 inhibitors for treating or preventing viral infections
WO2015073528A1 (en) 2013-11-12 2015-05-21 Proteostasis Therapeutics, Inc. Proteasome activity enhancing compounds
KR20160015076A (ko) 2014-07-30 2016-02-12 삼성전자주식회사 c-Met 저해제의 효능 예측을 위한 바이오마커 Hsp90
KR102259232B1 (ko) 2014-08-25 2021-05-31 삼성전자주식회사 항 c-Met/항 Ang2 이중 특이 항체
US20190134003A1 (en) * 2016-05-18 2019-05-09 Esanex, Inc. Combination therapies using indazolylbenzamide derivatives for the treatment of cancer
EP3653611A1 (en) * 2018-11-15 2020-05-20 Centre National De La Recherche Scientifique Inhibitors of metallo-beta-lactamases
CN110105368B (zh) * 2019-05-09 2022-01-07 上海大学 去氧紫杉烷类似物及其制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272083A1 (en) * 2004-06-04 2005-12-08 Somasekar Seshagiri EGFR mutations
US20080004266A1 (en) * 2006-05-25 2008-01-03 Zhenjian Du Method for treating proliferative disorders associated with protooncogene products
US20090232906A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
ME01498B (me) 2004-11-18 2014-04-20 Synta Pharmaceuticals Corp Jedinjenja triazola koja modulišu aktivnost hsp90
EP2193135A1 (en) 2007-08-13 2010-06-09 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
ES2331041B1 (es) 2008-03-11 2010-10-01 Fco. Javier Gil Vizuete Dispositivo para la extraccion de personas en emergencia vital y procedimiento de utilizacion.
NZ622713A (en) * 2009-10-19 2015-07-31 Synta Pharmaceuticals Corp Combination cancer therapy with hsp90 inhibitory compounds
WO2011133521A2 (en) * 2010-04-19 2011-10-27 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a hsp90 inhibitory compounds and a vegf inhibitor
US9205086B2 (en) * 2010-04-19 2015-12-08 Synta Pharmaceuticals Corp. Cancer therapy using a combination of a Hsp90 inhibitory compounds and a EGFR inhibitor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050272083A1 (en) * 2004-06-04 2005-12-08 Somasekar Seshagiri EGFR mutations
US20080004266A1 (en) * 2006-05-25 2008-01-03 Zhenjian Du Method for treating proliferative disorders associated with protooncogene products
US20090232906A1 (en) * 2008-03-14 2009-09-17 Bionumerik Pharmaceuticals, Inc. Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SYNTA PHARMACEUTICALS Press Release. 12 January 2010. [Retrieved from internet on 09 December 2013 - URL: http://phx.corporate-ir.net/phoenix.zhtml?c=147988&p=irol-newsArticle&ID=1374026&highlight *

Also Published As

Publication number Publication date
US20120064175A1 (en) 2012-03-15
CA2810254A1 (en) 2012-03-22
AU2011302344A1 (en) 2013-03-28
JP2013537229A (ja) 2013-09-30
CN103269701A (zh) 2013-08-28
EP2616063A1 (en) 2013-07-24
WO2012037072A1 (en) 2012-03-22

Similar Documents

Publication Publication Date Title
AU2011302344B2 (en) HSP90 inhibitors for treating non-small cell lung cancers in wild-type EGFR and/or KRAS patients
US10500193B2 (en) Combination therapy of HSP90 inhibitors with platinum-containing agents
US9402831B2 (en) Combination therapy of HSP90 inhibitors with BRAF inhibitors
US9439899B2 (en) Cancer therapy using a combination of HSP90 inhibitors with topoisomerase I inhibitors
US20150283147A1 (en) Treating polycystic kidney disease with hsp90 inhibitory compounds
US20130171105A1 (en) Cancer therapy using a combination of a hsp90 inhibitory compound and a topoisomerase ii inhibitor
US20150150850A1 (en) Treating cancer with hsp90 inhibitory compounds
US20140228418A1 (en) Combination therapy of hsp90 inhibitory compounds with mek inhibitors
CA2871540A1 (en) Treating cancer with hsp90 inhibitory compounds
AU2011255438A1 (en) Method of treating lung adenocarcinoma with Hsp90 inhibitory compounds

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired